Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: Implications for therapeutic trials

Neuromuscular Disorders

Volumn 24, Issue 7, 2014, Pages 604-610

  Hogrel, Jean Yves ^a   Allenbach, Yves ^a,b   Canal, Aurélie ^a   Leroux, Gaëlle ^b   Ollivier, Gwenn ^a   Mariampillai, Kuberaka ^a,b   Servais, Laurent ^a   Herson, Serge ^a,b   Decostre, Valérie ^a   Benveniste, Olivier ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Dynamometry; Inclusion body myositis; Natural history; Outcome measures; Strength

Indexed keywords

AGED; ANKLE EXTENSION; ANKLE FLEXION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DYNAMOMETRY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; INCLUSION BODY MYOSITIS; ISOMETRICS; KNEE EXTENSION; KNEE EXTENSION STRENGTH; KNEE FUNCTION; LONGITUDINAL STUDY; MALE; MUSCLE STRENGTH; MUSCULOSKELETAL FUNCTION; MUSCULOSKELETAL SYSTEM PARAMETERS; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; SCORING SYSTEM; SIX MINUTE WALK DISTANCE; ANKLE; DYNAMOMETER; EXERCISE TEST; KNEE; MOTOR ACTIVITY; MYOSITIS, INCLUSION BODY; NONLINEAR SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; SKELETAL MUSCLE; WALKING; WRIST;

AGED; ANKLE; DISEASE PROGRESSION; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HUMANS; KNEE; LONGITUDINAL STUDIES; MALE; MOTOR ACTIVITY; MUSCLE STRENGTH; MUSCLE STRENGTH DYNAMOMETER; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; NONLINEAR DYNAMICS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; WALKING; WRIST;

EID: 84901983707     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.04.009     Document Type: Article

References (18)

1. Flachenecker P. Epidemiology of neuroimmunological diseases. J Neurol 2006, 253(Suppl 5):V2-V8.
2. Askanas V., Engel W.K., Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009, 19:493-506.
3. Benveniste O., Guiguet M., Freebody J., et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011, 134:3176-3184.
4. Allenbach Y., Benveniste O., Decostre V., et al. Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. Neuromuscul Disord 2012, 22:980-986.
5. Cortese A., Machado P., Morrow J., et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord 2013, 23:404-412.
6. Lowes L.P., Alfano L., Viollet L., et al. Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis. Muscle Nerve 2012, 45:163-168.
7. Felice K.J., North W.A. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine (Baltimore) 2001, 80:320-327.
8. Lindberg C., Persson L.I., Bjorkander J., Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994, 89:123-131.
9. Peng A., Koffman B.M., Malley J.D., Dalakas M.C. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000, 55:296-298.
10. Rose M.R., McDermott M.P., Thornton C.A., Palenski C., Martens W.B., Griggs R.C. A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology 2001, 57:548-550.
11. Dalakas M.C., Rakocevic G., Schmidt J., et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion body myositis. Brain 2009, 132:1536-1544.
12. McDonald C.M., Henricson E.K., Abresch R.T., et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 2013, 48:343-356.
13. Servais L., Deconinck N., Moraux A., et al. Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients. Neuromuscul Disord 2013, 23:139-148.
14. Lindeman E., Leffers P., Reulen J., Spaans F., Drukker J. Quadriceps strength and timed motor performances in myotonic dystrophy, Charcot-Marie-Tooth disease, and healthy subjects. Clin Rehabil 1998, 12:127-135.
15. Alfano L.N., Lowes L.P., Dvorchik I., et al. The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis. Neuromuscul Disord 2014, 24:222-226.
16. Spector S.A., Lemmer J.T., Koffman B.M., et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997, 20:1242-1248.
17. Martin H.J., Yule V., Syddall H.E., Dennison E.M., Cooper C., Aihie Sayer A. Is hand-held dynamometry useful for the measurement of quadriceps strength in older people? A comparison with the gold standard Bodex dynamometry. Gerontology 2006, 52:154-159.
18. Toonstra J, Mattacola CG. Test-retest reliability and validity of isometric knee flexion and extension measurement using three methods of assessing muscle strength. J Sport Rehabil; 2013;Tech, Report 7.